We cooperate with the French company Pharnext and Alibaba Cloud to create a comprehensive information analysis platform that combines biomedical big data, artificial intelligence, and network pharmacology - CloudPhar. By means of novel technology based on disease target network, we assist R&D personnel to obtain data in different fields in a comprehensive, accurate and timely manner, offer modern biomedical analysis tools automated by AI; use the network model to comprehensively assess big data analysis results; complete pharmaceutical research and development with high more efficiently and precisely; promote system integration in the research and development chain from drug discovery to the launch of new drugs and contribute to the creation of a symbiotic global life and health ecosystem.

Focusing on innovative stem cell technologies, Tasly Stem Cell Platform aims to build itself into a leading digital stem cell quality platform.  Based on the impact of the micro-environment on dryness of stem cell, it strictly controls the sources of raw materials, standardizes the process of stem cell preparation, personalizes clinical applications of stem cell and creates an authoritative standard for the quality and applications of stem cell.  We lead the development of regenerative medicine by the model of “research and production for treatment” so as to make everyone benefit from cutting-edge pharmaceutical innovations and promote upgrading of the pharmaceutical industry. 

Tasly Regenerative Medicine Platform has completed the layout of the whole industrial chain of stem cells, and promoted the research and development of stem cells from different sources such as fat, bone marrow and umbilical cord at full speed.